Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Fractures, Bone

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Multiple Myeloma

Breast Neoplasms

Osteoporosis, Ovarian Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neovascularization, Pathologic

Breast Neoplasms, Multiple Myeloma, Pain, Prostatic Neoplasms

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Bone Diseases, Breast Neoplasms

Breast Neoplasms, Pain

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Pain, Prostatic Neoplasms

Breast Neoplasms, Prostatic Neoplasms

Breast Neoplasms, Osteoporosis

Breast Neoplasms, Osteoporosis

Breast Neoplasms

Breast Neoplasms

Metastatic Breast Cancer With Bone Involvement

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Osteoporosis

Breast Neoplasms, Neoplasm Micrometastasis

Humoral Hypercalcemia Of Malignancy, Breast Neoplasms, Neoplasm Metastasis, Pain

Breast Neoplasms, Osteoporosis

Bone Diseases, Metabolic, Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Multiple Myeloma, Pain, Prostatic Neoplasms

Breast Neoplasms, Osteoporosis

Breast Neoplasms

Breast Neoplasms

Clinical Trials

REaCT-ZOL

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year

Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries

NEO-ZOTAC

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

NEOZOL

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)

ER11-03

ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer

Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases

Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer

Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer

Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer

SuBDuE

NATAN

Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

CTIBL

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer

Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases

Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density

Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer

Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole

Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis